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Abstract
17b-Estradiol (E2) attenuates hypoxia-induced pulmonary
hypertension (HPH) through estrogen receptor (ER)-dependent
effects, including inhibition of hypoxia-induced endothelial cell
proliferation; however, the mechanisms responsible for this remain
unknown. We hypothesized that the protective effects of E2 in HPH
are mediated through hypoxia-inducible factor 1a (HIF-1a)-
dependent increases in ERb expression. Sprague-Dawley rats and
ERa or ERb knockout mice were exposed to hypobaric hypoxia
for 2–3 weeks. The effects of hypoxia were also studied in primary
rat or human pulmonary artery endothelial cells (PAECs).
Hypoxia increased expression of ERb, but not ERa, in lungs from
HPH rats as well as in rat and human PAECs. ERbmRNA time
dependently increased in PAECs exposed to hypoxia. Normoxic
HIF-1a/HIF-2a stabilization increased PAEC ERb, whereas HIF-1a
knockdown decreased ERb abundance in hypoxic PAECs. In turn,
ERb knockdown in hypoxic PAECs increased HIF-2a expression,
suggesting a hypoxia-sensitive feedback mechanism. ERb
knockdown in hypoxic PAECs also decreased expression of the HIF
inhibitor prolyl hydroxylase 2 (PHD2), whereas ERb activation
increased PHD2 and decreased bothHIF-1a andHIF-2a, suggesting
that ERb regulates the PHD2/HIF-1a/HIF-2a axis during hypoxia.
Whereas hypoxic wild-type or ERa knockout mice treated with E2
demonstrated less pulmonary vascular remodeling and decreased
HIF-1a after hypoxia compared with untreated hypoxic mice, ERb
knockout mice exhibited increased HIF-2a and an attenuated
response to E2 during hypoxia. Taken together, our results
demonstrate a novel and potentially therapeutically targetable
mechanismwhereby hypoxia, viaHIF-1a, increases ERb expression
and the E2-ERb axis targets PHD2, HIF-1a, and HIF-2a to
attenuate HPH development.
Keywords: hypoxia-inducible factor 1a; hypoxia-inducible
factor 2a; pulmonary hypertension; prolyl hydroxylase 2; 17b-
estradiol
Clinical Relevance
Our study has three important clinical implications. First, we
identify a novel and lung-speciﬁc estrogen receptor b response
to hypoxia that may explain the protective effects driven
by estrogen in hypoxia-induced pulmonary hypertension.
This ﬁnding has potential therapeutic implications because
although hypoxia-induced pulmonary hypertension is one
of the most common forms of pulmonary hypertension
worldwide, no therapeutic options exist. Second, our results
are the ﬁrst to link estrogen receptor to the regulation of
hypoxia-inducible factor 2. Third, our results may help solve
the “estrogen paradox” in pulmonary arterial hypertension.
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Pulmonary hypertension (PH) encompasses
a heterogeneous group of pulmonary
vascular disorders characterized by
increased vasoconstriction and aberrant
muscularization of the pulmonary arteries
(PAs) that lead to increased right ventricular
afterload and, if left untreated, right
ventricular failure and death (1–3). Several
forms of PH are characterized by sexual
dimorphism. For example, hypoxia-
induced PH (HPH), one of the most
common forms of PH worldwide (4–6),
is less common and less severe in females
(reviewed in Reference 7). On the other
hand, pulmonary arterial hypertension
(PAH), a progressive vasculopathy
characterized by uncontrolled endothelial
proliferation, obliterative PA lesions, and
markedly elevated PA pressures, exhibits a
female/male ratio that ranges from 1.4 to
4.1:1 (reviewed in Reference 7). These
disparate observations have been attributed
to dichotomous and tissue-dependent
effects of 17b-estradiol (E2) and its
receptors (estrogen receptor a [ERa] and
ERb). For example, although E2 may have
detrimental effects on the pulmonary
vasculature in the context of a BMPR2
mutation (8, 9), it has favorable ER-
dependent effects on pulmonary vascular
tone and PA endothelial cell (PAEC)
homeostasis in hypoxic conditions (10–13).
Interestingly, E2’s vasculoprotective
effects on PAECs are not observed during
normoxic conditions, indicating that E2
exerts speciﬁc actions during hypoxia that
may not be active during nonhypoxic
conditions. Further studies of the speciﬁc
effects of hypoxia on E2 signaling in the
pulmonary vasculature are therefore of
crucial importance, as such investigations
may 1) identify potential novel therapeutic
targets for HPH and PH induced by
chronic lung diseases, and 2) elucidate
whether alterations in the E2-ER axis—
similarly to recently identiﬁed alterations in
estrogen metabolism (14, 15)—contribute
to the predisposition of females for PAH.
Given our recently reported observations
of hypoxia-speciﬁc and ER-mediated
protective E2 signaling in HPH (10, 16), we
aimed to identify whether and how hypoxia
affects ER expression and function in the
pulmonary vasculature.
ERa and ERb (encoded by the genes
Esr1 and Esr2, respectively) are proteins
that belong to the nuclear-receptor
superfamily of transcription factors and
are expressed in both sexes (17, 18). Two
subtypes exist, both of which are expressed
in the histologically normal lung, with
ERb purportedly being more abundant
than ERa (19–22). In addition to
differences in tissue expression patterns,
the two ERs also differ in their biological
functions (21–24). For instance, in the
setting of breast and prostate cancer,
ERa mediates proproliferative effects and
ERb mediates antiproliferative signaling
(25–28). Interestingly, ERb exhibits
relevant effects in PAECs. Speciﬁcally,
ERb mediates E2-induced increases in
endothelial nitric oxide synthase activity
and prostacyclin synthesis in fetal bovine
PAECs (29, 30), and attenuates ERK1/2
(p42/44 MAPK) activation in hypoxic
rat PAECs (10). Administration of a
selective ERb agonist replicates E2’s
inhibitory effects on hypoxic pulmonary
vasoconstriction in isolated rat PA rings,
and this effect is mediated in a nitric
oxide– and endothelium-dependent
manner (13). Lastly, in a rat model of
HPH, E2-mediated decreases in pulmonary
vascular remodeling were attenuated
after cotreatment with a selective ERb
antagonist (10).
These ﬁndings implicate a unique
pathway of ER-dependent signaling during
hypoxia that inhibits pulmonary vascular
remodeling. We sought to investigate
whether and how hypoxia affects ER
expression and function in vitro and
in vivo. We demonstrate for the ﬁrst
time that hypoxia upregulates ERb
expression in isolated PAECs as well
as in the pulmonary vasculature, and
that this increase is dependent on
hypoxia-inducible factor 1a (HIF-1a).
Furthermore, we provide the ﬁrst evidence
demonstrating that ERb decreases both
HIF-1a and HIF-2a in vitro and in vivo,
and is necessary for E2’s vasculoprotective
effects in a murine model of HPH.
This novel role of ERb in regulating
HIF-2a is of particular relevance because
dysregulated HIF-2a signaling has recently
been reported to be a potent driver of the
formation of obliterative lesions in PH (31,
32). Finally, we provide evidence that ERb
stimulates expression of the HIF-a
inhibitor prolyl hydroxylase 2 (PHD2) in
PAECs, thus identifying attenuation of
HIF-1a and HIF-2a signaling as a novel
mechanism of E2 action in the pulmonary
vasculature. Parts of this study have
been previously reported in abstract
form (33, 34).
Methods
Please refer to the data supplement for
details regarding the materials and methods
used in this work.
Animal Care
The animal studies were approved by
the Indiana University School of Medicine
Institutional Animal Care and Use
Committee, and adhered to the National
Institutes of Health guidelines for the care
and use of laboratory animals under the
Animal Welfare Act.
In Vivo Studies
The HPH model has been described
previously (10). Male Sprague-Dawley
rats (Charles River) or wild-type (WT),
Esr12/2, and Esr22/2 C57BL/6 mice
(Jackson Laboratories) were exposed to 2–3
weeks of hypobaric hypoxia, respectively.
A subgroup of mice were treated with E2
(75 mg/kg/d via subcutaneous pellets [10];
Innovative Research of America) for the
duration of hypoxia exposure.
In Vitro Studies
Primary rat PAECs (from Drs. Troy Stevens
and Diego Alvarez, University of South
Alabama) or human PAECs (Lonza) were
exposed to hypoxia (1% O2) using an
InvivO2 hypoxia workstation (Ruskinn,
Inc.) as described previously (10). Control
cells of identical passage/conﬂuence were
grown concomitantly under room-air
conditions. To verify that no detectable or
only minimal amounts of E2 were present
in the culture media, E2 concentrations
were quantiﬁed via ELISA (Calbiotech)
and by comparing levels with those from
E2-treated media (see Fig. E1 in the data
supplement). Cells were treated with
deferoxamine (DFO; 10–100 mM;
Sigma-Aldrich) for 24 hours in room
air or with the selective ERb agonist
diarylpropionitrile (DPN; 1–100 nM; Tocris)
for 48 hours at 1–5% O2. Cells were transfected
using Lipofectamine 2000 with siHIF-1a or
siERb (ThermoFisher) for 24 hours and
exposed to hypoxia for 24–48 hours.
Immunocytochemistry
Rat or human PAECs were seeded on
gelatin-coated coverslips and exposed to
room air or hypoxia. The EC phenotype
was conﬁrmed (Figure E2). Primary
antibodies against ERa or ERb (1:200; Santa
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Cruz) were used. Alexa Fluor 488 conjugated
anti-rabbit secondary antibody (1:200;
ThermoFisher) and DAPI (ThermoFisher)
mounting media were used. Ten ﬁelds per
slide were taken using a Nikon microscope
at 403 . ER expression was quantiﬁed as the
average megapixel intensity per number
of nuclei by ImageJ (National Institutes
of Health).
Immunohistochemistry
Lung sections were stained with ERa (1:500,
Santa Cruz) or ERb (1:10; Dako) and
quantiﬁed using Metamorph software.
WT, Esr12/2, and Esr22/2 mouse lungs
were stained for a-smooth muscle actin
(1:500; Abcam). Quantiﬁcation was
performed as previously described (10).
Western Blotting
Tissue/cell lysis was performed as previously
described (10). The following antibodies
were used: ERa (1:1,000; Santa Cruz), ERb
(1:1,000; Santa Cruz), HIF-1a and HIF2-a
(1:1,000; Novus Biological), PHD2 (1:1,000;
Abcam), and vinculin (1:5000; Calbiochem).
Densitometry was performed via ImageJ.
Real-Time qRT-PCR
Total RNA was isolated from rat and
human PAECs using the RNeasy Plus Mini
Kit (Qiagen), and 1 mg total RNA was
reverse transcribed using the iScript cDNA
synthesis kit (Bio-Rad). TaqMan gene
expression assays for Esr1, Esr2, and 18S
(ThermoFisher; for assay IDs, see the data
supplement) were used. Changes in
mRNA expression were determined by
the comparative CT (22ΔΔCT) method and
expressed as the fold change compared
with normoxic controls.
Statistical Analyses
Results are expressed as means 6 SEM.
At least three independent experiments
(run in duplicates) were performed for all
in vitro studies. Statistical analyses were
performed with GraphPad Prism 6 (La Jolla,
CA). Student’s t test or one-way ANOVA with
Tukey’s post hoc or Dunnett’s correction were
used when appropriate. Statistical signiﬁcance
was accepted at P , 0.05.
Results
Hypoxia Increases ERb, but Not ERa,
in Rat Lungs
Our previous studies in HPH rats suggested
that hypoxia may upregulate ERb protein in
the pulmonary vasculature (10). To further
investigate this ﬁnding, we evaluated
lung ERa and ERb protein expression in
chronically hypoxic Sprague-Dawley rats by
immunohistochemistry and Western blot.
Although 2 weeks of hypoxia tended to
decrease lung ERa abundance (Figures 1A–
1C), hypoxia robustly increased the lung
expression of ERb (Figures 1A and 1D–1E).
ERb staining localized to PAECs, suggesting
that ERb is predominantly expressed in
these cells. The hypoxia-induced increase in
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Figure 1. Hypoxia increases expression of estrogen receptor b (ERb), but not ERa, in the lung. (A) Representative immunohistochemistry images of lung
sections from normoxic and hypoxic animals stained for ERa and ERb. Note the increase in ERb-positive cells (arrow) in pulmonary arteries from hypoxic rats.
Positive staining for ERb was mainly present in endothelial cells, and there was no significant staining of smooth muscle cells. (B–E) Protein expression of
(B) ERa and (D) ERb in whole-lung homogenates from rats exposed to 2 weeks of normoxia (fraction of inspired oxygen [FIO2] 21%) or chronic hypobaric
hypoxia (Patm = 362 mm Hg; equivalent to 10% FIO2). Quantification of (C) lung ERa and (E) ERb by densitometry is shown. Images were obtained at
3 40 magnification. Scale bars = 50 mm; n = 4/group. Error bars in scatterplots are means 6 SEM. *P , 0.05 versus normoxia control by t test.
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ERb was lung speciﬁc, as no increase was
noted in the right ventricle (RV), left
ventricle, or liver (Figure E3). In fact, ERb
expression was signiﬁcantly decreased in the
RV and liver, suggesting differential effects
of hypoxia on ERb expression in the lung
versus other organ systems.
Hypoxia Increases Expression of
ERb, but Not ERa, in Primary Rat and
Human PAECs
Because ERb appeared to be primarily
expressed in PAECs and upregulated under
hypoxic conditions, we next evaluated the
effect of hypoxia on ER expression in
primary rat PAECs. Rat PAECs were
cultured under hypoxic conditions (1% O2)
for 4, 24, or 72 hours, and ER expression
was evaluated by immunocytochemistry.
As was observed in vivo, ERa was not
signiﬁcantly affected by hypoxia exposure
compared with normoxic controls (Figures
2A and 2B). In contrast, hypoxia time
dependently increased ERb protein
compared with normoxic controls (Figures
2A and 2B). Interestingly, this hypoxia-
induced increase in ERb expression was
accompanied by a localization pattern
suggestive of nuclear translocation (Figures
2A and 2C). To investigate whether the
hypoxia-induced upregulation of ERb is
transcriptionally regulated, we used real-
time RT-PCR to quantify ERb mRNA. As
expected, ERb mRNA was signiﬁcantly
increased in rat PAECs at 24 hours (but
not at the earlier time point of 16 h;
Figure 2D), suggesting that the hypoxia-
induced increase in ERb is mediated by a
transcriptional mechanism. This increase
was speciﬁc to ERb, as similar increases in
ERa mRNA expression were not observed
(Figure 2D).
To corroborate these ﬁndings, we
cultured human primary PAECs under
hypoxic conditions for 24 or 72 hours, and
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Figure 2. Hypoxia increases expression of ERb, but not ERa, in cultured rat pulmonary artery endothelial cells (PAECs). (A) Representative
immunocytochemistry images of PAECs at 24 and 72 hours of hypoxia (1% O2) versus normoxia. ERa (left three columns) and ERb (right three
columns) are in green. Note the significant increase in ERb staining intensity in hypoxic cells, with a pattern of ERb staining suggestive of increased
nuclear translocation (arrows). (B) Time course of hypoxia-induced expression of ERa (black bars) and ERb (gray bars) by immunocytochemistry.
ERb expression was quantified by normalizing the megapixel intensity (MPI) by the number of cells (nuclei stained with DAPI) with ImageJ, and is
expressed as the fold change of MPI at 4, 24, and 72 hours versus MPI at corresponding normoxia time points. (C) ER nuclear translocation was
quantified as percent ER stain colocalized with DAPI. (D) ERa and ERb gene expression in rat PAECs measured by real-time qRT-PCR. Scale bars =
10 mm. Data are from three independent experiments and are presented as means 6 SEM. *P , 0.05 versus normoxia control by one-way ANOVA
with post hoc Tukey’s test.
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evaluated ERa and ERb expression by
immunocytochemistry and Western blot.
As in the rat PAECs, hypoxia selectively
and time dependently increased ERb
(but not ERa) expression, with a trend
toward an increase at 24 hours and a
signiﬁcant 25% increase at 72 hours
(Figures 3A and 3B). As in the rat PAECs,
immunocytochemistry studies suggested
that the hypoxia-induced increase in ERb
abundance was paralleled by a change
in ERb’s cellular localization pattern
consistent with translocation to the nucleus
(Figures 3A and 3C). In fact, 80% of the
ERb-positive cells colocalized with DAPI
at 24 hours, and this was maintained even
at 72 hours. Finally, we quantiﬁed the
changes in ERb expression using real-time
RT-PCR. Similar to what was observed with
rat PAECs, ERb, but not ERa, mRNA
was signiﬁcantly increased at 24 hours
(but not at the earlier time point of 4 h;
Figure 3D), suggesting that the hypoxia-
induced increase in ERb is transcriptionally
regulated. Interestingly, we also observed
hypoxic induction of ERb, but not ERa,
protein in human pulmonary
microvascular endothelial cells (PMVECs;
Figure E4) and pulmonary smooth
muscle cells (data not shown) at 72 hours,
indicating that the speciﬁc hypoxic
regulation of ERb is relevant to multiple
cell types/phenotypes in the pulmonary
vasculature. Taken together, these data
indicate that hypoxia 1) selectively increases
ERb mRNA and protein in cultured
primary PAECs, and 2) results in nuclear
translocation of ERb, suggesting that this
receptor has biologically relevant effects in
the context of hypoxia.
Normoxic HIF-a Stabilization Is
Sufﬁcient to Increase ERb in Rat
PAECs
We next sought to determine whether the
hypoxia-induced increase in rat PAEC ERb
expression is driven by HIF-1a, a master
regulator of hypoxia-driven responses (35).
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Figure 3. Hypoxia increases expression of ERb, but not ERa, in primary human PAECs. (A) Representative immunocytochemistry images of human
PAECs at 24 and 72 hours of hypoxia (1% O2) versus normoxia. ERa (left three columns) or ERb (right three columns) are in green. Note a pattern of ERb
staining suggestive of increased nuclear translocation (arrows). (B) Time course of hypoxia-induced expression of ERa (black bars) and ERb (gray bars).
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MPI at 4, 24, and 72 hours versus MPI at corresponding normoxia time points. (C) ER nuclear translocation was quantified as percent ER stain colocalized
with DAPI. (D) ERa and ERb gene expression in rat PAECs measured by real-time qRT-PCR. Scale bars = 10 mm. Data are from three independent
experiments and are presented as means 6 SEM. *P , 0.05 versus normoxia control by one-way ANOVA with post hoc Tukey’s test.
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We treated rat PAECs with the iron chelator
DFO, which leads to normoxic HIF-a
stabilization (Figures 4A and 4B). Indeed,
DFO treatment (10 mM for 24 h) resulted in
a robust 25% increase in ERb (Figures 4A
and 4D). DFO leads to stabilization of
HIF-2a and, similar to the case with HIF-1a,
we detected the stabilization of HIF-2a in
rat PAECs after DFO treatment (Figures 4A
and 4C), indicating that normoxic HIF-a
stabilization is sufﬁcient to increase ERb
expression.
HIF-1a Is Necessary for the Hypoxia-
induced Increase in ERb Expression
in Rat PAECs
To examine whether HIF-1a is necessary
for the hypoxia-induced increase in ERb,
we used siRNA directed against HIF-1a in
rat PAECs grown under hypoxic conditions
(Figures 5A and 5B). As expected, knockdown
of HIF-1a attenuated the hypoxia-induced
increase in ERb at 24 and 48 hours of
hypoxia (Figures 5A and 5C), suggesting
that HIF-1a indeed is necessary for hypoxia
to increase ERb.
ERb Decreases HIF-2a and Increases
PHD2 in Rat PAECs
To determine whether ERb in turn affects
HIF-1a expression during hypoxia, we used
siRNA directed against ERb. Interestingly,
knockdown of ERb during hypoxia resulted
in decreased expression of HIF-1a at 24 (but
not 48) hours of hypoxia exposure (Figures
5A and 5B), suggesting that HIF-1a is
time dependently under the control of ERb.
We next assessed whether the HIF-a family
member HIF-2a is regulated by ERb.
Although HIF-2a was decreased after
24 hours of ERb knockdown, we noted a
signiﬁcant 30% increase in HIF-2a protein
48 hours after ERb knockdown (Figures 5A
and 5D), suggesting that ERb regulates and
time dependently decreases HIF-2a. Because
PHD2 is a major inhibitor of HIF-a (by
mediating HIF-a degradation) (36), we next
sought to identify whether ERb also affects
PHD2 expression. Indeed, knockdown of
ERb during hypoxia resulted in 50%
decreased expression of PHD2 at both
24 and 48 hours (Figures 5A and 5E),
indicating that ERb regulates PHD2
expression. We corroborated these ﬁndings
by treating hypoxic rat PAECs for 48 hours
with the ERb-selective agonist DPN
(Figure 6). We noted a dose-dependent
increase in PHD2 expression in cells treated
with 100 nM of DPN (Figures 6A and 6B),
indicating that, indeed, ERb increases PHD2
expression in rat PAECs. We also observed
dose-dependent decreases in HIF-1a
(Figures 6A and 6C) and HIF-2a (Figures
6A and 6D) expression in cells treated with
DPN. Given the potential inactivation of
PHD2 in severe hypoxic conditions (37), we
also tested the effect of DPN on PHD2,
HIF-1a, and HIF-2a expression under less
severe hypoxic conditions (5% O2; Figure E5).
Similar to our observations at 1% O2, we
observed a dose-dependent increase in
PHD2 expression (Figures E5A and E5B), a
decrease in HIF-2a expression (Figures E5A
and E5D), and a trend toward decreased
HIF-1a expression (Figures E5A and E5C).
In summary, these data suggest that in
hypoxic rat PAECs, HIF-1a increases ERb,
and that ERb in turn decreases HIF-2a
and increases its inhibitor, PHD2. The data
for DPN, but not those for siERb, suggest
that ERb may also decrease HIF-1a. This
discrepancy may be due to a compensatory
upregulation of ERa or other factors after
ERb knockdown, or it may indicate a time-
dependent differential effect of ERb on
HIF-1a expression.
ERb Is Necessary for E2 to Attenuate
Hypoxia-induced Pulmonary Vascular
Remodeling and Decrease Lung
HIF-1a and HIF-2a Expression
To corroborate our ﬁndings in vivo, we
treated Esr12/2 or Esr22/2 mice (mice
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Figure 4. Hypoxia-inducible factor 1a (HIF-1a) stabilization under normoxic conditions increases ERb expression in cultured rat PAECs. Effects of
treatment with deferoxamine (DFO; 10 or 100 mM for 24 h) or vehicle (veh; H2O) on HIF-1a (A and B), HIF-2a (A and C), and ERb (A and D) expression are
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containing germline null mutations
for ERa or ERb, respectively) and WT
mice with E2 (75 mg/kg/day [10]),
and exposed them to 3 weeks of hypoxia
(Patm = 362 mm Hg). An additional group
of untreated WT mice were placed in
hypoxia to serve as controls. As previously
noted in chronically hypoxic rats, compared
with hypoxic WT controls, E2 treatment in
WT mice signiﬁcantly decreased hypoxia-
induced pulmonary vascular remodeling by
40% (Figures 7A and 7B). Importantly, this
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reduction in pulmonary vascular
remodeling was observed in E2-treated
Esr12/2, but not Esr22/2, mice (Figures 7A
and 7B), suggesting that ERb is required
for E2 to attenuate hypoxia-induced
pulmonary vascular remodeling. Contrary
to our hypothesis, PHD2 was not affected
by E2 or loss of ERa or ERb (Figures 7C
and 7D), suggesting that PHD2 is not solely
regulated by E2-ER signaling. Alternatively,
it is possible that E2-ER–mediated changes
in PHD2 expression in PAECs in vivo were
not captured at the time point investigated,
or were masked by surrounding tissue in
whole-lung homogenates. On the other
hand, E2 treatment in hypoxic WT mice
tended to decrease lung HIF-1a and HIF-
2a expression (Figures 7C, 7E, and 7F),
and in the case of HIF-1a, resulted in a
signiﬁcant 50% decrease in E2-treated
Esr12/2 mice (where E2 signaling occurs
through ERb; Figures 7C and 7E).
However, E2 did not lower HIF-1a
abundance in Esr22/2 mice (where E2
signaling occurs through ERa; Figures 7C
and 7E). In parallel, E2 treatment led to
increased HIF-2a expression in Esr22/2
mice (Figures 7C and 7F). This suggests
that ERb is required for E2 to decrease
HIF-2a and HIF-1a expression. However,
in the latter case, this effect can only occur in
the absence of ERa, indicating that 1) ERa
has effects opposite to those of ERb and
actually increases HIF-1a, and 2) ERa and
ERb compete with each other for E2 binding.
Taken together, these studies demonstrate
that ERb is required for E2 to attenuate
hypoxia-induced pulmonary vascular
remodeling, is necessary for E2 to decrease
lung HIF-a expression, and prevents
increases in lung HIF-2a expression.
Discussion
Our studies reveal that ERb, but not ERa, is
upregulated in hypoxic rat lung, cultured
hypoxic rat and human conduit PAECs,
and PMVECs. We show for the ﬁrst time
that HIF-a chemical stabilization with DFO
is sufﬁcient to induce ERb expression and
that knockdown of HIF-1a by siRNA
reduces ERb expression in hypoxic PAECs,
identifying that the hypoxia-induced
increase in ERb expression occurs via a
HIF-a–dependent mechanism. Additionally,
we provide novel evidence suggesting
that HIF-2a is downregulated and PHD2
is upregulated by ERb in vitro. siRNA
directed against ERb leads to the robust
upregulation of HIF-2a and downregulation
of PHD2 in hypoxic PAECs, and treatment
with the ERb agonist DPN upregulates
PHD2 expression and decreases HIF-1a and
HIF-2a in a dose-dependent manner. Lastly,
we demonstrate that ERb is necessary for E2
to attenuate hypoxia-induced pulmonary
vascular remodeling, decrease lung HIF-1a,
and prevent increases in HIF-2a expression.
However, the decrease in HIF-1a in vivo
only occurred in the absence of ERa. Taken
together, these novel data implicate ERb
as a mediator of protective E2 signaling in
the hypoxic pulmonary vasculature. A
schematic of the putative interaction among
hypoxia, ERb, HIF-1a, HIF-2a, and PHD2
in the pulmonary vasculature is provided
in Figure E6.
HPH is prevalent globally; it affects
millions of people living at high altitude and
millions of patients afﬂicted with a wide
spectrum of chronic lung disease and
sleep-disordered breathing (5). HPH is
characterized by signiﬁcant pulmonary
vascular remodeling that may culminate in
right ventricular failure and death (4, 38).
Although it occurs much more frequently
than PAH (39), no speciﬁc treatment for
HPH exists. In fact, therapeutics used for
PAH frequently worsen oxygenation in
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HPH (40–42), indicating a need for novel
therapeutic approaches to HPH. Several
clinical and preclinical studies have
identiﬁed that female sex confers a
protective phenotype during acute or
chronic hypoxia exposure (reviewed in
Reference 7). For example, in multiple
species, females exhibit less hypoxic
pulmonary vasoconstriction and are
protected from HPH. These effects have
been linked to vasodilator and
antiproliferative effects of E2 (7). For
example, pregnancy attenuates hypoxic
pulmonary vasoconstriction, ovariectomy
worsens HPH, and E2 repletion attenuates
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HPH (reviewed in References 7 and 43).
A better understanding of the effects of E2
and its receptors in the hypoxic pulmonary
vasculature could provide the rationale
and basis for future studies focused on
developing novel therapeutic strategies for
HPH.
We previously demonstrated that
E2 attenuates HPH via an ER-dependent
mechanism (10), and recently expanded
upon that ﬁnding by discovering an ER-
dependent genome in lungs from HPH rats
(16). Of note, our previous data showed
that E2 exerts speciﬁc antiproliferative
effects during hypoxia that are not evident
during normoxia (10). For example, E2-ER
dependently decreased bromodeoxyuridine
uptake and vascular endothelial growth
factor secretion in hypoxic rat PAECs, but
not in PAECs grown in room air. Our
current data expand upon these ﬁndings
and suggest that hypoxia-enabled increases
in ERb expression may allow for E2 to exert
its hypoxia-speciﬁc effects. Such a ﬁnding
may explain why E2 has consistently been
shown to be protective in hypoxia models
of PH, whereas its effects in other types of
PH have been less consistent (reviewed in
Reference 7).
If ERb signaling can be protective in
the pulmonary vasculature, this raises the
possibility that alterations in ERb signaling
may contribute to the female predominance
noted in PAH. Of note, SNPs in ESR22/2
have been associated with LV structural
differences in women with hypertension
(44) and with increased arterial stiffness in
Framingham Offspring Study participants
(45). This suggests that genetic alterations
in ESR22/2 could also contribute to
abnormalities in the pulmonary vasculature.
Alternatively, in the absence of hypoxia-
enabled increases in ERb expression, E2’s
protective signaling pathways may not be
engaged, allowing for the development of
pulmonary vascular disease, especially in the
context of otherwise predisposing conditions
for PAH development (e.g., genetic
abnormalities and environmental exposures).
To the best of our knowledge, our
studies are the ﬁrst to implicate HIF-1a
as a regulator of ERb in PAECs. Given
that HIF-1a is a key regulator of hypoxia-
mediated effects, this ﬁnding is not entirely
surprising. Our ﬁndings are consistent with
results from studies in HEK293 cells, which
demonstrated that HIF-1a transcriptionally
activates ERb expression in the absence of
E2, and the addition of E2 did not further
enhance the upregulation of ERb (46).
Subsequent studies in other cell types have
linked HIF-1a to the induction of ERb
independently of E2 (47–49). For instance,
in human ER-positive breast cancer cells,
hypoxia stimulated ERb expression and
reduced ERa expression (48), whereas in
human stromal cells isolated from patients
with endometriosis, hypoxia strongly
induced ERb (47), both in the absence
of E2. Additionally, steroid receptor
coactivator-1 and CREB-binding protein
comprise part of the HIF-1a transcriptional
coactivator complex and can promote ERb
transcription in the absence of E2 (49).
Building on these observations, we
performed PROMO and TRANSFAC
in silico promoter analyses, which identiﬁed
two putative HIF-1a binding sites in the
ESR2 promoter (Ensembl ENSG00000140009)
to be validated in future studies.
Interestingly, we did not observe a
signiﬁcant increase in ERb mRNA
expression until 16 hours (human PAECs)
or 24 hours (rat PAECs) after hypoxia. One
explanation for this slow upregulation is
that because ERb expression is regulated by
multiple coactivators and corepressors,
there may be a transcriptional repressor
complex at the ERb promoter upon the
ﬁrst, acute induction of HIF-1a due to
hypoxia that is not present at a later,
chronic hypoxia time point. Finally, we
cannot completely rule out that the trace
amounts of E2 detected in rat PAEC media
(Fig. E1; likely arising as a result of
endogenous PAEC E2 synthesis via
aromatase [50]) activated ERb. However,
this seems unlikely, as no E2 was detected
in human PAEC media, yet hypoxia
increased ERb expression and induced its
translocation in this cell type as well.
Together, these data suggest that ERb,
independently of the presence of E2, is
encoded by a hypoxia-responsive gene.
The ﬁnding that ERb in turn regulates
HIF-1a and HIF-2a in vitro and
in vivo reveals a novel and potentially
therapeutically targetable mechanism of
action in the hypoxic pulmonary
vasculature that may explain in part why E2
attenuates HPH and why females are
protected against the development of HPH.
This putative negative-feedback loop of
ERb on HIF-a likely occurs via direct
binding of HIF-1a to ERb, followed by the
nuclear translocation of ERb and binding
to estrogen response elements of target
genes. Interestingly, at least one study has
shown that the ERb protein is able to bind
directly to HIF-1a (46). Alternatively,
hypoxia could indirectly facilitate ERb
nuclear translocation via direct activation of
ERb by a HIF-1a–induced growth factor,
e.g., epidermal growth factor (51). The
negative-feedback mechanism we identiﬁed
is consistent with data from the oncology
literature, which demonstrates that ERb
inhibits HIF-1a transcriptional activity and
promotes its proteasome degradation in
prostate cancer cells (52). On the other
hand, to the best of our knowledge, we are
not aware of any prior data demonstrating
that ERb decreases HIF-2a. This is of
particular importance because dysregulated
HIF-2a signaling has been linked to the
formation of obliterative pulmonary
vascular lesions in PH (32). However, the
effects of ERb on HIF-1a and HIF-2a
were not clear-cut. At 24 hours of ERb
knockdown, both HIF-1a and HIF-2a were
decreased rather than increased, suggesting
a time dependence of ERb effects on these
transcription factors. In addition, ERb
knockdown did not lead to increased HIF-
1a at the 48-hour time point. This
phenomenon may be explained by competing
effects of ERa and ERb on HIF expression:
ERa (or another, as yet unidentiﬁed factor)
may compensate for the loss of ERb and
repress HIF-a. On the other hand, the
ﬁnding that selective ERb activation
decreased both HIF-1a and HIF-2a clearly
indicates that ERb exerts inhibitory effects
on these mediators.
The in vivo effects of E2 and ERb on
HIF-a were complex. E2 did not
statistically signiﬁcantly decrease HIF-1a in
hypoxic WT rats (even though there was a
trend), and a signiﬁcant decrease occurred
only in E2-treated Esr12/2 mice. Although
this could be the result of a type II error, it
may also suggest that ERa increases
HIF-1a. Speciﬁcally, ERa and ERb may
have opposing effects on HIF-1a in vivo,
allowing ERb to decrease HIF-1a only
in the absence of ERa. Such a paradigm
would be consistent with the known
proproliferative effects of ERa in prostate
cancer (28) and in PA smooth muscle cells
(53). An alternative hypothesis is that the
absence of ERa increases the abundance of
E2 at ERb, thus driving a more prominent
ERb signal. This would suggest that ERa
and ERb compete with each other for
binding to E2. Such a scenario is likely,
given that in the absence of ERb there is no
increase in HIF-1a (Figures 7C and 7F).
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Similarly, E2 did not statistically
signiﬁcantly decrease HIF-2a in vivo, yet,
again, there was a trend. In contrast to
HIF-1a, HIF-2a markedly increased in
E2-treated Esr22/2 mice. This indicates
that ERb exerts inhibitory effects on
HIF-2a and suggests that ERa and ERb
may have opposing effects on HIF-2a
in vivo, with ERa exerting stimulatory
effects and ERb preventing this increase.
Our data suggest that the inhibitory
effect of ERb on HIF-1a and HIF-2a
may be mediated by PHD2. PHDs
hydroxylate HIF-1a and HIF-2a, leading to
von Hippel–Lindau protein-dependent
ubiquitination and rapid proteasomal
degradation (35). Three main isoforms
exist, with PHD2 being the most prominent
isoform (36). Interestingly, we found that
ERb induces PHD2 in hypoxic PAECs.
This may, in turn, downregulate HIF-1a
and HIF-2a. This ﬁnding is supported
by recently published data from prostate
epithelial cells demonstrating that ERb
promotes HIF-1a degradation by
increasing PHD2 transcription and by
identifying an estrogen response element in
the PHD2 promoter (52). Given the recent
report that PHD2 expressed in PAECs
protects against PAH development (32),
our identiﬁcation of PHD2 as a target of
ERb is of particular interest, as it suggests a
novel mechanism whereby E2 attenuates
HPH development.
ERb may also inhibit HIF-1a and
HIF-2a through PHD2-independent
mechanisms. For example, ERb was shown
to inhibit HIF-1a transcriptional activity via
downregulation of ARNT (HIF-1b) (54). In
another study, ERb was shown to destabilize
HIF-1a protein via proteasomal degradation
(55). It is possible that similar mechanisms
regulate ERb’s effects on HIF-1a in the
hypoxic pulmonary vasculature. Future
studies will focus on identifying the exact
molecular mechanisms of ERb-mediated
attenuation of HIF-1a and HIF-2a in the
hypoxic lung and in hypoxic PAECs.
Our study has several limitations.
First, although our in vitro data robustly
identify PHD2 as a target of ERb, we did
not detect any changes in PHD2 expression
in Esr12/2 or Esr22/2 mice treated with
E2. Although it is possible that PHD2 is
not regulated by E2-ERb signaling in vivo,
we consider it more likely that E2-ERb–
mediated changes in PHD2 expression in
PAECs in vivo were not captured at the
time point investigated, or were masked
by surrounding tissue in whole-lung
homogenates. This is supported by the
observation that the effects we noted on
HIF-1a and HIF-2a were robust in vitro as
well as in vivo. Second, our in vitro studies
used a severe level of hypoxia (1% O2). This
severe level of hypoxia can inhibit PHD2
activity at least acutely (at 4 h), but perhaps
not chronically (36, 37, 56), which could
be a source of variability in our data;
however, we were able to corroborate our
DPN ﬁndings using less severe hypoxic
conditions (5% O2), during which PHD2
should be active (Figure E3). Second, in our
studies we used in vitro rat and human
primary cells, and conducted in vivo studies
in rats and mice; however, it should be
noted we did not use human cells for all
studies. Future investigations will focus on
expanding upon these mechanisms in
human PAECs and PMVECS, and in
patients with HPH under less severe
hypoxic conditions. Third, although we
conﬁrmed that hypoxia upregulates ERb in
several cell types and in two species, we did
not corroborate our mechanistic studies in
human cells. We did, however, conﬁrm the
relevance of this signaling pathway in vivo,
making the rat PAEC studies relevant.
Mechanistic studies dissecting the interplay
among HIFs, PHD, and ERb in PAECs
from healthy donors and patients with PH
are currently ongoing in our laboratory.
To eliminate potentially confounding
effects of estrogens or the estrous cycle on
ER expression, we performed the current
study in male animals, and therefore do
not provide information on ER expression
in hypoxic females. Similarly, our
commercially obtained human PAECs and
PMVECs were derived from male donors.
Studies in females are currently underway,
and a sex-speciﬁc comparison of ER
expression will be the focus of future
investigations. Lastly, our studies focused
on hypoxia-induced changes in the
pulmonary vasculature and are therefore
relevant for HPH and WHO group 3 PH,
but cannot necessarily be extrapolated to
PAH. Given that HIF-1a, HIF-2a, and
female sex play major roles in PAH
development, the cross-talk among HIF-1a,
HIF-2a, E2, and ERb in this disease needs
to be explored further. The protective ERb
signaling noted in hypoxia may be lost or
altered in PAH.
In summary, we provide the ﬁrst
evidence of a novel HIF-1a–dependent
hypoxia pathway that induces ERb, but not
ERa, in PAECs and PMVECs. We show that
the hypoxia-induced upregulation of ERb
is speciﬁc to the lung and pulmonary
vasculature, as evidenced by the decrease
in ERb expression in the hypoxic RV and
liver. We demonstrate that ERb induces
expression of the HIF-a inhibitor PHD2 and
decreases HIF-1a and HIF-2a expression
in vitro. In vivo, ERb prevents increases in
HIF-2a and is necessary for E2 to decrease
lung HIF-1a and hypoxia-induced pulmonary
vascular remodeling. Harnessing these
pathways may facilitate the development of
speciﬁc therapeutic strategies for patients
with HPH and WHO group 3 PH, for
whom there are no pharmacological
treatment options, and help unravel the
“estrogen paradox” in PAH. n
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